Anthrogenesis Corporation

Celularity Inc.

Clarity Acquisition Ii LLC

Lin Kang

Xiaokui Zhang

Robert J Hariri

Andrew L Zeitlin

Brian P Murphy

James W Edinger

Vanessa R Voskinarian-Berse

Mohammad A Heidaran

Stewart Abbot

Ajai Pal

Eric Law

Vanessa A Voskinarian-Berse

Neerav Dilip Padliya

Bhavani Stout

Stephen Jasko

Vanessa Voskinarian-Berse

Steven Alan Fischkoff

Uri Herzberg

Vladimir Jankovic

Wolfgang Hofgartner

Andy Zeitlin

Ivana Djuretic

Stewart Ernest Abbott

Mohamad Hussein

Han Myint

Keith Wilson

Andrea Nordberg

Steven Jasko

Neerav Dilip Padlina

Henry Rendon Barrigan

Vanessa Voskinarian-berse

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL-2.

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Method of producing erythrocytes without feeder cells

Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.

Natural killer cells from placenta

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

Methods of generating natural killer cells

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Method of producing erythrocytes

Growing community of inventors

Edison, NJ, United States of America

Lin Kang